“I never imagined experiencing such a revolution!”
Amandine Luquiens, addiction psychiatrist at Nîmes University Hospital, is enthusiastic: she has just taken care of the very first patient* in a pioneering study in France on psychotherapy assisted by psilocybin, the active substance in hallucinogenic mushrooms.
Carried out at the Grau-du-Roi Rehabilitation, Re-education and Addictology Hospital (Gard) on 30 patients suffering from alcohol use disorders associated with depression, this will firstly to study
the “feasibility and acceptability”
of the treatment before it is eventually evaluated in a larger cohort.
“We include patients whose addiction is severe and in whom signs of depression remain present after withdrawal, which is a major risk factor for relapse
,” specifies Dr. Luquiens.
On average, almost half of alcohol-dependent patients relapse within 6 months following withdrawal, and a third of patients…
This article is reserved for subscribers.
You have 88% left to discover.
Flash sale
-70% on digital subscription
I ENJOY IT
Already subscribed?
Log in